GLP1R and psoriasis: Such a broad spectrum of multidirectional anti-inflammatory and anti-oxidative incretin-based therapies, especially GLP1R agonists, opens new avenues for their use in other diseases, including autoimmune disease (as reviewed for example by Ranbdaksh et al. and McLean et al. with respect to autoimmune thyroid diseases, inflammatory bowel diseases, psoriasis, rheumatoid arthritis, late autoimmune diabetes in adults [LADA], asthma, multiple sclerosis and psoriasis) [131,132].